Omar Y Mian

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6287816/publications.pdf

Version: 2024-02-01

51 papers	1,007 citations	430874 18 h-index	454955 30 g-index
51 all docs	51 docs citations	51 times ranked	2041 citing authors

#	Article	IF	Citations
1	Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. Journal of Urology, 2022, 207, 541-550.	0.4	30
2	125I Interstitial brachytherapy with or without androgen deprivation therapy among unfavorable-intermediate and high-risk prostate cancer. Brachytherapy, 2022, 21, 85-93.	0.5	3
3	Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia. Journal of Clinical Investigation, 2022, 132, .	8.2	15
4	Phase II Study of ONC201 in Neuroendocrine Tumors including Pheochromocytoma-Paraganglioma and Desmoplastic Small Round Cell Tumor. Clinical Cancer Research, 2022, 28, 1773-1782.	7.0	11
5	A genomic classifier for prostate cancer correlates with adverse pathologic features: Transcriptomic features of cribriform and intraductal carcinoma of the prostate.. Journal of Clinical Oncology, 2022, 40, 268-268.	1.6	0
6	Prognostic factors and clinical outcomes in patients with upper tract urothelial carcinoma undergoing surgery: The Cleveland Clinic experience.. Journal of Clinical Oncology, 2022, 40, 4593-4593.	1.6	0
7	Responses to the 2018 and 2019 â€œOne Big Discoveryâ€•Question: ASTRO Membershipâ€™s Opinions on the Most Important Research Question Facing Radiation Oncologyâ€¦Where Are We Headed?. International Journal of Radiation Oncology Biology Physics, 2021, 109, 38-40.	0.8	4
8	Current Landscape and Future Directions on Bladder Sparing Approaches to Muscle-Invasive Bladder Cancer. Current Treatment Options in Oncology, 2021, 22, 3.	3.0	3
9	The Nexus of Endocrine Signaling and Cancer: How Steroid Hormones Influence Genomic Stability. Endocrinology, 2021, 162, .	2.8	14
10	A Therapeutic Strategy for Preferential Targeting of TET2-Mutant and TET Dioxygenaseâ€“Deficient Cells in Myeloid Neoplasms. Blood Cancer Discovery, 2021, 2, 146-161.	5.0	36
11	Therapeutic Targeting of TET-Dioxygenase Deficiency in Myeloid Malignancies. Blood, 2021, 138, 3985-3985.	1.4	1
12	Yes, Nodal Recurrence of Prostate Cancer is Potentially Curable. International Journal of Radiation Oncology Biology Physics, 2020, 106, 238.	0.8	0
13	Analysis of Spatial Dose-Volume Relationships and Decline in Sexual Function Following Permanent Brachytherapy for Prostate Cancer. Urology, 2020, 135, 111-116.	1.0	0
14	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 262-268.	1.6	15
15	Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 lowÂdose rate brachytherapy monotherapy. Brachytherapy, 2020, 19, 43-50.	0.5	15
16	Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nature Communications, 2020, 11, 2393.	12.8	60
17	The effect of antibiotic use on immune-checkpoint inhibitor efficacy in patients with advanced urothelial carcinoma.. Journal of Clinical Oncology, 2020, 38, e17116-e17116.	1.6	0
18	Management of Oligometastatic Prostate Cancer. Applied Radiation Oncology, 2020, 9, 6-10.	0.5	3

#	Article	IF	Citations
19	The landscape of early carcinogenesis revealed through the lens of integrative genomics, epigenomics, and transcriptomics. Journal of Thoracic Disease, 2019, 11, 2188-2191.	1.4	1
20	Analysis of the 2017 American Society for Radiation Oncology (ASTRO) Research Portfolio. International Journal of Radiation Oncology Biology Physics, 2019, 103, 297-304.	0.8	5
21	Correlation between MRI phenotypes and a genomic classifier of prostate cancer: preliminary findings. European Radiology, 2019, 29, 4861-4870.	4.5	23
22	Ten-Year Outcomes of Moderately Hypofractionated (70ÂGy in 28 fractions) Intensity Modulated Radiation Therapy for Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 104, 325-333.	0.8	23
23	Molecular Characterization of Neuroendocrine-like Bladder Cancer. Clinical Cancer Research, 2019, 25, 3908-3920.	7.0	71
24	The ASTRO Research Portfolio: Where Do We Go From Here?. International Journal of Radiation Oncology Biology Physics, 2019, 103, 308-309.	0.8	1
25	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical Cancer Research, 2019, 25, 210-221.	7.0	48
26	Impact of Cribriform Pattern and Intraductal Carcinoma on Gleason 7 Prostate Cancer Treated with External Beam Radiotherapy. Journal of Urology, 2019, 202, 710-716.	0.4	31
27	Bladder-sparing treatment of nonmetastatic muscle-invasive bladder cancer. Clinical Advances in Hematology and Oncology, 2019, 17, 697-707.	0.3	5
28	Reductions in prostatic doses are associated with less acute morbidity in patients undergoing Pd-103 brachytherapy: Substantiation of the rationale for focal therapy. Brachytherapy, 2018, 17, 313-318.	0.5	7
29	Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy. Practical Radiation Oncology, 2018, 8, e159-e165.	2.1	1
30	Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. Advances in Radiation Oncology, 2018, 3, 601-610.	1.2	5
31	Responses to the 2017 â€œ1 Million Gray Questionâ€• ASTRO Membership's Opinions on the Most Important Research Question Facing Radiation Oncology. International Journal of Radiation Oncology Biology Physics, 2018, 102, 249-250.	0.8	1
32	Case study: patient-derived clear cell adenocarcinoma xenograft model longitudinally predicts treatment response. Npj Precision Oncology, 2018, 2, 14.	5.4	22
33	Intraoperative Registered Ultrasound and Fluoroscopy (iRUF) for dose calculation during prostate brachytherapy: Improved accuracy compared to standard ultrasound-based dosimetry. Radiotherapy and Oncology, 2017, 124, 61-67.	0.6	8
34	The evolving role of molecular profiling in prostate cancer: basal and luminal subtyping transcends tissue of origin. Translational Cancer Research, 2017, 6, S1441-S1445.	1.0	6
35	Timely stereotactic body radiotherapy (SBRT) for spine metastases using a rapidly deployable automated planning algorithm. SpringerPlus, 2016, 5, 1337.	1.2	2
36	GSTP1 Loss results in accumulation of oxidative DNA base damage and promotes prostate cancer cell survival following exposure to protracted oxidative stress. Prostate, 2016, 76, 199-206.	2.3	45

#	Article	IF	Citations
37	Prevalence of Substance Use in Patients With Cancer Receiving Radiation Therapy. Clinical Journal of Oncology Nursing, 2016, 20, 397-402.	0.6	5
38	Computed tomography imaging assessment of postexternal beam radiation changes of the liver. Future Oncology, 2016, 12, 2729-2739.	2.4	9
39	Androgen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation. Clinical Cancer Research, 2016, 22, 3310-3319.	7.0	37
40	Dosimetric predictors of sexual function decline following LDR brachytherapy for prostate cancer (PCa).. Journal of Clinical Oncology, 2016, 34, 113-113.	1.6	0
41	An image-guidance system for dynamic dose calculation in prostate brachytherapy using ultrasound and fluoroscopy. Medical Physics, 2014, 41, 091712.	3.0	18
42	Management Options in Locally Advanced Pancreatic Cancer. Current Oncology Reports, 2014, 16, 388.	4.0	29
43	Pre and postradiation lymphopenia predicts survival in management of bone metastases.. Journal of Clinical Oncology, 2014, 32, 9563-9563.	1.6	0
44	The human sodium-dependent ascorbic acid transporters SLC23A1 and SLC23A2 do not mediate ascorbic acid release in the proximal renal epithelial cell. Physiological Reports, 2013, 1, e00136.	1.7	15
45	Methyl-Binding Domain Protein 2â€“Dependent Proliferation and Survival of Breast Cancer Cells. Molecular Cancer Research, 2011, 9, 1152-1162.	3.4	40
46	Chapter 4 The Role of the Epigenetic Signal, DNA Methylation, in Gene Regulation During Erythroid Development. Current Topics in Developmental Biology, 2008, 82, 85-116.	2.2	23
47	Atherosclerotic Plaque Macrophage Transcriptional Regulators Are Expressed in Blood and Modulated by Tristetraprolin. Circulation Research, 2006, 98, 1282-1289.	4.5	43
48	Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Molecular and Cellular Biochemistry, 2005, 273, 25-32.	3.1	125
49	Circulating transcriptome reveals markers of atherosclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 3423-3428.	7.1	88
50	Current and Future Applications of SAGE to Cardiovascular Medicine. Trends in Cardiovascular Medicine, 2003, 13, 163-168.	4.9	8
51	Serial Analysis of Gene Expression. Circulation Research, 2002, 91, 565-569.	4.5	52